It has been reported FGFR3 mutations were more common in noninvasive BLCA and related to a better BLCA prognosis, and patients with FGFR3 mutant tumors could benefit from anti-FGFR3 therapy (44, 45). Here, FGFR3 is linked to bladder transitional cell carcinoma.